Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SafiledCriticalSanofi Sa
Publication of AR109252A1publicationCriticalpatent/AR109252A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicinal Preparation
(AREA)
Abstract
Reivindicación 1: Una formulación de anticuerpo adecuada para la administración subcutánea a un paciente, comprendiendo la formulación: a) de aproximadamente 50 a aproximadamente 250 mg/mL de un anticuerpo anti-CXCR5 o un fragmento del mismo; b) un tampón de citrato; c) tensioactivo a más de aproximadamente 0,01% (p/v); d) aminoácido más de aproximadamente 50 mM; y e) sucrosa a más de aproximadamente 1%, en donde el pH de la formulación es aproximadamente pH 6.Claim 1: An antibody formulation suitable for subcutaneous administration to a patient, the formulation comprising: a) from about 50 to about 250 mg / mL of an anti-CXCR5 antibody or a fragment thereof; b) a citrate buffer; c) surfactant at more than about 0.01% (w / v); d) amino acid more than about 50 mM; and e) sucrose at more than about 1%, wherein the pH of the formulation is about pH 6.
ARP170101846A2016-07-052017-07-04
FORMULATIONS OF ANTIBODIES
AR109252A1
(en)
Reduction of the viscosity of pharmaceutical formulations that comprise a therapeutic protein at a concentration of at least 70 mg / ml, where the therapeutic protein is not an antibody (divisional application 201700984)